"Adalimumab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A humanized monoclonal antibody that binds specifically to TNF-ALPHA and blocks its interaction with endogenous TNF RECEPTORS to modulate INFLAMMATION. It is used in the treatment of RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS; CROHN'S DISEASE and ULCERATIVE COLITIS.
| Descriptor ID |
D000068879
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.060.250 D12.776.124.790.651.114.224.060.250 D12.776.377.715.548.114.224.200.250
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Adalimumab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Adalimumab [D12.776.124.486.485.114.224.060.250]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Adalimumab [D12.776.124.790.651.114.224.060.250]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Adalimumab [D12.776.377.715.548.114.224.200.250]
Below are MeSH descriptors whose meaning is more specific than "Adalimumab".
This graph shows the total number of publications written about "Adalimumab" by people in this website by year, and whether "Adalimumab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2011 | 0 | 3 | 3 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 1 | 2 |
| 2018 | 2 | 0 | 2 |
| 2020 | 0 | 2 | 2 |
| 2021 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adalimumab" by people in Profiles.
-
Godoy-Brewer G, Salem G, Limketkai B, Selaru FM, Grossen A, Policarpo T, Haq Z, Parian AM. Use of Biologics for the Treatment of Inflammatory Conditions of the Pouch: A Systematic Review. J Clin Gastroenterol. 2024 02 01; 58(2):183-194.
-
Dal?n J, Chitkara A, Svedbom A, Olofsson T, Puenpatom A, Black CM, Qureshi ZP. Health-Care and Societal Costs Associated with Non-Persistence with Subcutaneous TNF-a Inhibitors in the Treatment of Inflammatory Arthritis (IA): A Retrospective Observational Study. Adv Ther. 2022 06; 39(6):2468-2486.
-
Hoque S, Puenpatom A, Boccaletti S, Green C, Black CM, Roberts J, Rajkovic I, Milligan G. Treatment persistence and colectomy-free outcomes in patients with ulcerative colitis receiving golimumab or adalimumab: a UK experience. BMJ Open Gastroenterol. 2020 11; 7(1).
-
Dal?n J, Luttropp K, Svedbom A, Black CM, Kachroo S. Healthcare-Related Costs Associated with Switching Subcutaneous Tumor Necrosis Factor-a Inhibitor in the Treatment of Inflammatory Arthritis: a Retrospective Study. Adv Ther. 2020 09; 37(9):3746-3760.
-
Starr MR, Smith WM. Histoplasmosis Following Systemic Immunomodulatory Therapy for Ocular Inflammation. Am J Ophthalmol. 2019 02; 198:88-96.
-
Farquhar DR, Taylor JM, Mazul AL, Zevallos JP. HPV-Positive Oropharyngeal Squamous Cell Carcinoma among Patients Taking Adalimumab for Autoimmune Disorders. Otolaryngol Head Neck Surg. 2018 09; 159(3):593-594.
-
Black CM, Yu E, McCann E, Kachroo S. Dose Escalation and Healthcare Resource Use among Ulcerative Colitis Patients Treated with Adalimumab in English Hospitals: An Analysis of Real-World Data. PLoS One. 2016; 11(2):e0149692.
-
Dal?n J, Svedbom A, Black CM, Lyu R, Ding Q, Sajjan S, Sazonov V, Kachroo S. Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence. Rheumatol Int. 2016 Jul; 36(7):987-95.
-
George MD, Cardenas AM, Birnbaum BK, Gluckman SJ. Ureaplasma septic arthritis in an immunosuppressed patient with juvenile idiopathic arthritis. J Clin Rheumatol. 2015 Jun; 21(4):221-4.
-
Rosenstein RK, Panush RS, Kramer N, Rosenstein ED. Hypereosinophilia and seroconversion of rheumatoid arthritis. Clin Rheumatol. 2014 Nov; 33(11):1685-8.